110
Views
36
CrossRef citations to date
0
Altmetric
Review

11β-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents

&
Pages 1407-1422 | Published online: 06 Dec 2007
 

Abstract

11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) plays an essential role in regulating the access of glucocorticoids to nuclear receptors. Chronically elevated levels of glucocorticoids cause obesity, diabetes, cardiovascular disease (the metabolic syndrome) and impairments in memory. Dysregulation of 11β-HSD1 has been implicated in all of these disease states. Studies with transgenic mice have demonstrated that overexpression of 11β-HSD1 in adipose tissue produces the metabolic syndrome, while knockout of the enzyme produces mice with a cardioprotective phenotype that resist cognitive decline with ageing. Studies with selective 11β-HSD1 inhibitors have demonstrated that it is possible to lower plasma glucose and triglyceride levels as well as food intake and the rate of body weight gain. Consequently, 11β-HSD1 is an important target for the treatment of the metabolic syndrome and cognitive impairment, with many companies pursuing the development of inhibitors. This patent review focuses on the large number of patents published since 2005.

Notes

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,757.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.